

RESEARCH

Open Access



Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine

Grace Mzumara^{1,6*}, James Chirombo¹, Todd D. Swarthout^{5,7}, Naor Bar-Zeev^{1,2,8}, Philliness Prisca Harawa^{1,3}, Mohamed Sanusi Jalloh⁴, Amir Kirolos², Victoria Mukhula¹, Laura Newberry¹, Olawale Ogunlade^{4,9}, Richard Wachepa¹, Neil French², Robert S. Heyderman^{5,10} and Pui-Ying Iroh Tam^{1,3,4,11^}

Abstract

Background The 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced in Malawi in 2011 with an expected impact of reducing pneumococcal pneumonia in children. We aimed to describe clinical characteristics and nasopharyngeal (NP) carriage of pneumococcus by serotype in children hospitalized with primary end-point pneumonia (PEP) between 2013 and 19 after the introduction of PCV-13.

Methods We conducted a secondary analysis of children aged under-5-years hospitalized with acute respiratory illness (ARI) in Malawi. Chest radiographs conducted at admission were read by two independent clinicians according to WHO criteria for PEP, and a third reviewer resolved discordant diagnoses. NP swab specimens were processed and *Streptococcus pneumoniae* growth was serotyped. Multivariable regression analysis was conducted to assess the association between clinical characteristics, NP serotypes, and PEP.

Results We had complete radiographic and NP serotype data for 500 children, of which 54 isolates were vaccine-type (VT) (10.8%), 165 were non-VT (NVT; 33.0%), and 281 had no pneumococcal growth (56.2%). Among these, 176 (35.2%) had PEP on chest x-ray. Among those with PEP, pneumococcal carriage was documented in 43.8% of cases, and VT serotypes accounted for 10.8%. For children with PEP, we found no association between clinical characteristics and carrying either VT, NVT, or no pneumococcus.

[^]Pui-Ying Iroh Tam sadly deceased before publication of this work was completed. We would like to particularly acknowledge her expertise in devising and completing this work, and, in mentoring young researchers.

*Correspondence:

Grace Mzumara
gmzumara@mlw.mw

Full list of author information is available at the end of the article



© The Author(s) 2024, corrected publication 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Conclusion Carriage of *S. pneumoniae* remains high among children hospitalized with ARI in Malawi, but children with VT carriage were no more likely to have PEP than children carrying no pneumococcus or those with NVT carriage. There were no differences in clinical characteristics between those carrying VT, NVT, or no pneumococcus.

Keywords Pneumococcal conjugate vaccine, Radiographic pneumonia, Respiratory illness, Serotypes, Sub-Saharan Africa, Child

Introduction

Pneumonia is the leading cause of mortality globally among children older than one month [1, 2] with *Streptococcus pneumoniae* being the leading causative pathogen. While the clinical diagnosis of pneumonia is insensitive and nonspecific [3, 4], chest radiography has been shown to be reliable in identifying lobar pneumonia [1, 5].

In low- and middle-income country settings, there were reductions in pneumococcal pneumonia severity and mortality after introduction of pneumococcal conjugate vaccines (PCV) [6–11], as well as childhood primary end-point pneumonia (PEP) [11, 12]. The World Health Organization defines PEP as ‘the presence of end point consolidation or pleural effusion in the lateral pleural space’ [13]. End point consolidation is defined as ‘a dense or fluffy opacity that occupies a portion or whole of a lobe or entire lung that may or may not contain an air bronchogram’ [13].

In Malawi, after the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced into the infant vaccination programme in November 2011 [14, 15], surveillance studies demonstrated high residual nasopharyngeal (NP) carriage of vaccine serotypes (VTs) in PCV-13-vaccinated children [16, 17], and a predominance of non-vaccine serotypes (NVTs) [16–18]. Furthermore, pneumococcal serotypes vary in NP carriage prevalence, invasiveness, and disease incidence [19, 20]. The more invasive serotypes causing more severe disease were therefore selected for inclusion in the conjugate vaccines.

There is lack of data in sub-Saharan Africa on the pneumococcal serotypes seen in children with radiographic PEP, on whether radiographic PEP is seen more commonly among VT or NVT, and whether clinical characteristics of radiographic PEP differ between VT and NVT. The objective of this study was to determine the odds of PEP in children with VT compared with NVT carriage, and to evaluate whether clinical characteristics differ between children with radiographic PEP due to VT v. NVT. We hypothesized that radiographic PEP would be more common in VT than NVT carriers, consistent with the greater invasiveness of these serotypes, and that clinical characteristics in radiographic PEP may differ between VT and NVT.

Methods

Study design

This study is a secondary analysis of data collected from two studies on acute respiratory illness (ARI) in Blantyre, Malawi between 2013 and 2019. ARI was defined as having a fever of over 38 °C and cough with onset of less than 10 days.

The first study, VacSurv, was a case-control study of children ≤ 5 years hospitalized with clinical diagnosis of severe ARI at Queen Elizabeth Central Hospital carried out between 2013 and 2016 [18]. Clinical and demographic data, chest x-rays (CXR), and NP swabs were collected. For every case enrolled at hospitalization, there were four otherwise healthy controls enrolled from the community, matched by age and neighbourhood [18].

The second study, a series of rolling pneumococcal carriage surveys (PCVPA), was a surveillance study carried out between 2015 and 2019, that investigated the impact of PCV-13 on pneumococcal carriage and disease in children and adults in the community after vaccine introduction [17]. Concomitantly with the community cohort, PCVPA enrolled a hospital cohort among children 1–4 years of age who were clinically diagnosed with severe ARI on presentation. Clinical and sociodemographic data, CXRs, blood, and NP swabs were collected [17]. NP swabs were collected for all children at admission to hospital with respiratory signs, and were also collected for healthy community controls [17, 18].

All NP samples were processed at the Malawi-Liverpool Wellcome Programme laboratory following WHO recommendations and as described elsewhere [18]. Presence of *S. pneumoniae* was determined by culture growth on NP swab, and isolates were serotyped and categorized as VT or NVT.

Chest radiography

Eight clinicians (NBZ, PH, MJ, AK, GM, VM, LN, OO) read CXRs, following the methodology and training provided by the WHO Chest Radiography in Epidemiological Studies (CRES, <https://who-cres.mcri.edu.au/>) [13]. CXRs from both VacSurv and PCVPA were each read in duplicate, and any disagreements were resolved by a third read. In addition, 10% of CXRs were randomly selected for quality control reads. CXRs were read as either PEP, other infiltrate, or no pathology. We defined no PEP as a CXR with other infiltrate or no pathology.

Statistical analysis

We conducted multivariable regression analysis to assess the association between PEP and VT v. NVT. Stata v.18 (College Station, TX: Statacorp LLC) was used for data analysis. P-values of <0.05 were considered statistically significant.

Ethics

This study was approved by the College of Medicine Research Ethics Committee (P.02/15/1677) and the Liverpool School of Tropical Medicine Research Ethics Committee (14.056). Ethical approval for the primary studies PCVPA and VacSurv was obtained by the National Health Sciences Research Committee (protocol 867), the College of Medicine Research Ethics Committee

(P.01/08/609 and P.09/09/826), and the University of Liverpool Research Ethics Committee (RETH490). Written informed consent was obtained from the parents/guardians of participants.

Results

There were a total of 1,088 children enrolled in the VacSurv case-control study, and 1,224 children enrolled in the PCVPA hospital cohort (Fig. 1). CXRs were collected for 873 children in VacSurv and 654 children in PCVPA. A total of 358 CXRs scored as PEP, 120 (13.7%) in VacSurv and 238 (36.4%) in PCVPA. After merging and aligning variables across both datasets, we had complete CXR and NP serotype data for 500 children. Only one death was recorded.




Fig. 1 Flow diagram of data included in the analysis

Table 1 Primary end-point pneumonia in children with VT v. NVT v. no pneumococcus

Nasopharyngeal carriage (%)	Non-primary endpoint pneumonia (n = 324)	Primary endpoint pneumonia (n = 176)	Odds ratio (95% CI)	P value
No pneumococcus	175 (54.0%)	106 (60.2%)	Reference	
VT serotypes	35 (10.8%)	19 (10.8%)	0.89 (0.46–1.64)	0.72
NVT serotypes	114 (35.2%)	51 (29.0%)	0.73 (0.49–1.11)	0.15

CI, confidence interval; NVT, non-vaccine type; VT, vaccine type

Table 2 Clinical characteristics of children with PEP due to VT v. NVT v. no pneumococcus

	Primary endpoint pneumonia (n = 176)			P value
	Nasopharyngeal carriage			
	No pneumococcus (n = 106)	VT (n = 19)	NVT (n = 51)	
Age in months, median (25th -75th IQR) ^a	28 Months (16.9–36.2)	22 Months (15.5–32.5)	20 Months (15.2–28.4)	0.16
Prior antibiotic use (n = 70)	44/106 (41.5%)	7/19 (36.8%)	19/51(37.2%)	0.61
Mother HIV positive (n = 26)	16/106 (15.1%)	4/19 (21.1%)	6/51 (11.8%)	0.31
Child HIV positive (n = 13)	8/106 (7.5%)	2/19 (10.5%)	3/51 (5.9%)	0.64
Fever (n = 125)	79/106 (74.5%)	12/19 (63.2%)	34/51 (66.7%)	0.43
Cough (n = 175)	105/106 (99.1%)	19/19 (100%)	51/51 (100%)	1.00
Apnoea (n = 3)	3/106 (2.8%)	0 (0%)	0 (0%)	0.68
Nasal flaring (n = 155)	94/106 (88.7%)	17/19 (89.5%)	44/51 (86.3%)	0.94
Chest indrawing (n = 152)	92/106 (86.8%)	16/19 (84.2%)	44/51 (86.3%)	0.95
Stridor (n = 2)	2/106 (1.9%)	0 (0%)	0 (0%)	1.00
Wheeze (n = 148)	90/106 (84.9%)	15/19 (78.9%)	43/51 (84.3%)	0.79
Bronchial breathing (n = 96)	57/106 (5.4%)	11/19 (57.9%)	28/51 (54.9%)	0.97
Reduced air entry (n = 106)	47/106 (44.3%)	10/19 (52.6%)	18/51 (35.3%)	0.38

IQR, interquartile range; HIV, human immunodeficiency virus; NVT, non-vaccine type; VT, vaccine type

^aOne-way ANOVA

Of the 500 NP swabs, *S. pneumoniae* was detected in 219 cases (43.8%). Of those, 54 were VT and 165 were NVT. The most common VT serotypes were 19 F with 21 cases (38.9%), 23 F with 9 cases (16.7%), 3 with 6 cases (11.1%), and 19 A with 5 cases (9.3%). There were three cases each (5.6%) of serotypes 6B and 14, and two cases each (3.7%) of serotypes 7 F, 5 and 6 A.

Among the 500 children, 176 had PEP (35.2%) and 324 had no PEP (64.8%) on CXR. Among those with PEP, 51 were NVT (28.9%), 19 were VT (10.8%), and 106 had no pneumococcal growth (60.2%). Among non-PEP cases, 114 were NVT (35.2%), 35 were VT (10.8%), and 175 (54.0%) had no pneumococcal growth. Compared to those without pneumococcus, neither those with VT (OR 0.89, 95% CI: 0.46–1.64) nor NVT (OR 0.73, 95% CI: 0.49–1.11) had increased odds of PEP (Table 1).

There were no differences in the clinical characteristics of those with PEP when comparing those carrying VT v NVT v no pneumococcus (Table 2), no differences in clinical characteristics between children with PEP and no-PEP (Supplementary Table 1), and no significant association between NP serotypes and PEP in children hospitalized with ARI (Supplementary Table 2).

Discussion

In this study, nearly half (43.5%) of children hospitalized with ARI had *S. pneumoniae* detected in their nasopharynx. PEP was detected in 10.8% of cases with VT serotypes and 29.0% of cases with NVT serotypes. However, no significant association was found between PEP and NP findings. Children with VT carriage were no more likely to have PEP than children carrying no pneumococcus or those with NVT carriage. There were no differences in clinical characteristics between those carrying VT v. NVT v. no pneumococcus.

This is the largest study in sub-Saharan Africa to evaluate pneumococcal serotypes in children hospitalized with ARI and the association with radiographic PEP. Pneumococcal serotypes vary in NP carriage prevalence, invasiveness, and disease incidence [19, 20], and therefore more invasive serotypes causing severe disease were selected for inclusion in conjugate vaccines.

In our analysis, VT serotypes accounted for 10.8% of radiographic PEP. A prior surveillance study in Malawi noted sustained VT carriage among infants, showing a post-PCV 13 carriage of 9.3% at 6–10 weeks compared to 24.2% before vaccine introduction (3). In the 1–4 year age group, VT carriage was sustained at 18.7% in a 2014 study and 16.5% in a 2018 study (3,4).

In PERCH, a pneumonia etiology study conducted in five sub-Saharan African countries (The Gambia, Mali, Zambia, South Africa, and Kenya), *S. pneumoniae* was the most common bacteria isolated, and one of the bacteria most associated with radiographic PEP [21, 22], but the role of pneumococcal serotypes was not specifically evaluated. Other studies in Malawi and from sub-Saharan Africa have evaluated serotypes in invasive pneumococcal disease [17, 23–25], or effects of PCV on radiographic PEP [26], but not serotype association with radiographic PEP.

Radiographic pneumonia and their associated pneumococcal serotypes have been described in adults in high-income countries [27, 28], and demographic and clinical characteristics between PCV-13 and non-PCV-13, or proposed expanded PCV serotypes in an adult hospitalized population, were noted to be similar [27, 29]. In Zanzibar, a study of serotype distribution in preschool children with radiologically confirmed pneumonia compared to healthy controls prior to introduction of pneumococcal vaccination identified PCV-13 serotypes 9 A/V and 14 to be significantly associated with radiographic pneumonia [30]. However, in this dataset 294 children had a CXR collected, and only 39 children had radiographic pneumonia [30]. Our study involving 500 CXRs and 176 cases of PEP is the largest to date conducted in sub-Saharan Africa.

This study had some limitations. We examined children following WHO criteria for diagnosis of PEP, which is the methodology used for epidemiology studies and not routinely used in clinical practice. This, therefore, could have underestimated the number of cases of lobar pneumonia in our dataset. We did not capture information on previous admissions with respiratory illness at the time of PEP diagnosis and that could have affected the association between PEP and clinical features present at the time of diagnosis. We did not conduct serotyping for all serotypes, and therefore could not comprehensively evaluate what additional serotype coverage beyond PCV-13 would be beneficial. PCV-13 was introduced in Malawi in 2011, and the decreased incidence of cases over the subsequent decade may have made differences in disease severity less apparent. Finally, due to differences in the variables used in the two studies, after merging and aligning variables across the datasets, only a proportion of cases were included in the final analysis.

In conclusion, among children hospitalized with ARI in Malawi after introduction of PCV-13, carriage of *S. pneumoniae* remains pervasive, with high prevalence of VT and NVT serotypes. VT serotypes accounted for a moderate proportion of radiographic PEP. Further research is needed to understand the basis for the continued carriage of VT serotypes after PCV-13 introduction and

evaluate interventions to reduce carriage and associated pneumonia morbidity and mortality.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s41479-024-00147-7>.

Supplementary Material 1

Acknowledgements

We thank Ivan Mambule, Brewster Moyo, and Clemens Masesa for assistance with data support, and Akuzike Kalizang'oma for assistance with specimen support. We thank the children and parents involved in PCVPA and VacSurv, the VacSurv Consortium, and the study team and clinical staff at Queen Elizabeth Central Hospital.

Author contributions

TDS, NBZ, NF, RSH led PCVPA and VacSurv studies. PI provided training for CXRs, which were read by AK, NBZ, PH, MSJ, GM, LN, OO, and VM. GM merged the data with support from RW. GM conducted the statistical analysis with support from JC, TDS, NF, RSH, and PI. GM wrote the first draft of the manuscript, with support from PI. All authors reviewed and contributed to the final draft.

Data availability

Data is provided within the manuscript.

Declarations

Competing interests

This work was funded by the Bill & Melinda Gates Foundation (OPP1117653 to RSH), a Wellcome Programme Grant (WT091909/B/10/Z to RSH), and National Institute for Health & Care Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government (16/136/46 to RSH), Wellcome Trust Programme Grant (WT091909/B/10/Z) to NF, RSH; an investigator initiated grant by GlaxoSmithKline Biologicals to NBZ, NF, and National Institute for Health Research. NBZ and NF received an investigator-initiated grant by GlaxoSmithKline Biologicals to support data collection. Malawi-Liverpool-Wellcome Programme is supported by a Strategic Award from Wellcome, UK (206545/Z/17/Z). PI received grant funding from Bill & Melinda Gates Foundation. For the remaining authors no competing interests were declared.

Author details

¹Malawi-Liverpool Wellcome Programme, Blantyre, Malawi

²University of Liverpool, Liverpool, UK

³Kamuzu University of Health Sciences, Blantyre, Malawi

⁴Liverpool School of Tropical Medicine, Liverpool, UK

⁵Department of Infection, Division of Infection and Immunity, University College London, London, UK

⁶Present address: University of Bergen, Bergen, Norway

⁷Present address: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands

⁸Present address: World Health Organization, Geneva, Switzerland

⁹Present address: International Committee of the Red Cross, Abuja, Nigeria

¹⁰Present address: University College London, London, UK

¹¹Present address: International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

Received: 6 May 2024 / Accepted: 12 September 2024

Published online: 05 October 2024

References

1. le Roux DM, Zar HJ. Community-acquired pneumonia in children - a changing spectrum of disease. *Pediatr Radiol*. 2017;47(11):1392–8.

2. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204–22.
3. Uwemedimo OT, Lewis TP, Essien EA, Chan GJ, Nsona H, Kruk ME, Leslie HH. Distribution and determinants of pneumonia diagnosis using Integrated Management of Childhood Illness guidelines: a nationally representative study in Malawi. *BMJ Glob Health*. 2018;3(2):e000506.
4. Kanyuka M, Ndawala J, Mleme T, Chisesa L, Makwemba M, Amouzou A, Borghi J, Daire J, Ferrabee R, Hazel E, et al. Malawi and Millennium Development goal 4: a countdown to 2015 country case study. *Lancet Glob Health*. 2016;4(3):e201–214.
5. Fancourt N, Deloria Knoll M, Barger-Kamate B, de Campo J, de Campo M, Diallo M, Ebruke BE, Feikin DR, Gleeson F, Gong W, et al. Standardized interpretation of chest radiographs in cases of Pediatric Pneumonia from the PERCH Study. *Clin Infect Dis*. 2017;64(suppl3):S253–61.
6. Roca A, Sigauque B, Quinto L, Morais L, Berenguer A, Corachan M, Ribo JL, Naniche D, Bassat Q, Sacoor C, et al. Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children. *Vaccine*. 2010;28(30):4851–7.
7. Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitskovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. *Vaccine*. 2008;26(38):4947–54.
8. Iliya J, Shatima DR, Tagbo BN, Ayede AI, Fagbohun AO, Rasaq A, Nalban S, Elon IW, Mohammed-Nafiu R, Ahmed P, et al. Pneumonia hospitalizations and mortality in children 3–24-month-old in Nigeria from 2013 to 2020: impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10). *Hum Vaccin Immunother*. 2023;19(1):2162289.
9. Hortal M, Estevan M, Meny M, Iraola I, Laurani H. Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay. *PLoS ONE*. 2014;9(6):e98567.
10. Erdman LK, D'Acremont V, Hayford K, Rajwans N, Kilowoko M, Kyungu E, Hongoa P, Alamo L, Streiner DL, Genton B, et al. Biomarkers of host response predict primary end-point Radiological Pneumonia in Tanzanian Children with Clinical Pneumonia: a prospective cohort study. *PLoS ONE*. 2015;10(9):e0137592.
11. Enwere G, Cheung YB, Zaman SM, Akano A, Oluwalana C, Brown O, Vaughan A, Adegbola R, Greenwood B, Cutts F. Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children. *Trop Med Int Health*. 2007;12(11):1377–85.
12. Awasthi S, Kohli N, Agarwal M, Pandey CM, Rastogi T, Pandey AK, Roy C, Mishra K, Verma N, Kumar CB, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine on radiological primary end-point pneumonia among cases of severe community acquired pneumonia in children: a prospective multi-site hospital-based test-negative study in Northern India. *PLoS ONE*. 2022;17(12):e0276911.
13. Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, Greenberg D, Lagos R, Lucero M, Madhi SA, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. *Bull World Health Organ*. 2005;83(5):353–9.
14. Office NS. Malawi Demographic and Health Survey 2015–16. In.; 2015.
15. Mvula H, Heinsbroek E, Chihana M, Crampin AC, Kabuluzi S, Chirwa G, Mwansambo C, Costello A, Cunliffe NA, Heyderman RS, et al. Predictors of Uptake and timeliness of newly introduced pneumococcal and Rotavirus vaccines, and of Measles Vaccine in Rural Malawi: a Population Cohort Study. *PLoS ONE*. 2016;11(5):e0154997.
16. Heinsbroek E, Tafatatha T, Phiri A, Swarthout TD, Alaerts M, Crampin AC, Chisambo C, Mwiba O, Read JM, French N. Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination. *Vaccine*. 2018;36(48):7369–76.
17. Swarthout TD, Fronterre C, Lourenco J, Obolski U, Gori A, Bar-Zeev N, Everett D, Kamng'ona AW, Mwalukomo TS, Mataya AA, et al. High residual carriage of vaccine-serotype *Streptococcus pneumoniae* after introduction of pneumococcal conjugate vaccine in Malawi. *Nat Commun*. 2020;11(1):2222.
18. Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, Bilima S, Mallewa J, King C, von Gottberg A, et al. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies. *Lancet Glob Health*. 2021;9(7):e989–98.
19. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-specific differences in invasive disease potential. *J Infect Dis*. 2003;187(9):1424–32.
20. Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Ruckinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. *Clin Infect Dis*. 2010;51(6):692–9.
21. Deloria Knoll M, Prosperi C, Baggett HC, Brooks WA, Feikin DR, Hammit LL, Howie SRC, Kotloff KL, Madhi SA, Murdoch DR, et al. Introduction to the site-specific etiologic results from the Pneumonia Etiology Research for Child Health (PERCH) study. *Pediatr Infect Dis J*. 2021;40(9S):S1–6.
22. Moore DP, Baillie VL, Mudau A, Wadula J, Adams T, Mangera S, Verwey C, Sipambo N, Liberty A, Prosperi C, et al. The etiology of Pneumonia in HIV-1-infected South African children in the era of antiretroviral treatment: findings from the Pneumonia Etiology Research for Child Health (PERCH) study. *Pediatr Infect Dis J*. 2021;40(9S):S69–78.
23. Chikhaoui A, Nzoyikorera N, Diawara I, Jouhadi Z, Zerouali K. Burden of invasive pneumococcal disease in children in Casablanca, Morocco four years after the introduction of pneumococcal vaccination. *Pan Afr Med J*. 2022;41:2.
24. Kirolos A, Swarthout TD, Mataya AA, Bonomali F, Brown C, Msefula J, Bar-Zeev N, Iroh Tam PY, Alaerts M, Bilima S, et al. Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi. *BMC Infect Dis*. 2023;23(1):56.
25. Raboba JL, Rahajamanana VL, Andriatahirintsoa EPR, Razafindrakoto AC, Andrianarivelo AM, Nimpa Mengouo M, Vuo Masembe Y, Weldegebriel GG, de Gouveia L, Mwenda JM, et al. Decline in vaccine-type *Streptococcus pneumoniae* serotypes following pneumococcal conjugate vaccine introduction in Madagascar. *J Infect Dis*. 2021;224(12 Suppl 2):S285–92.
26. Silaba M, Ooko M, Bottomley C, Sande J, Benamore R, Park K, Ignas J, Maitland K, Mturi N, Makumi A, et al. Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. *Lancet Glob Health*. 2019;7(3):e337–46.
27. Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L, Peyrani P, Ford KD, Pride MW, Self WH, et al. Expanded analysis of 20 pneumococcal serotypes Associated with Radiographically confirmed community-acquired Pneumonia in hospitalized US adults. *Clin Infect Dis*. 2021;73(7):1216–22.
28. Hansen K, Runow E, Torisson G, Theilacker C, Palmberg A, Pan K, Jiang Q, Southern J, Beavon R, Gessner BD, et al. Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016–2018-The ECAPS study. *Front Public Health*. 2023;11:1086648.
29. Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, Baskaran V, Edwards-Pritchard RC, Sheppard C, Eletu SD, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. *Thorax*. 2020;75(1):38–49.
30. Elfving K, Stromberg LG, Geravandi S, Andersson M, Bachelard M, Msellem M, Shakely D, Trollfors B, Norden R, Martensson A, et al. Pneumococcal concentration and serotype distribution in preschool children with radiologically confirmed pneumonia compared to healthy controls prior to introduction of pneumococcal vaccination in Zanzibar: an observational study. *BMC Infect Dis*. 2022;22(1):925.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.